We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-25.6%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$585M
AUM Growth
-$238M
Cap. Flow
-$19.6M
Cap. Flow %
-3.35%
Top 10 Hldgs %
58.39%
Holding
39
New
3
Increased
9
Reduced
8
Closed
8

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$13.8M
2
BLUE
bluebird bio
BLUE
+$8.53M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$7.16M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.54M
5
IBB icon
iShares Biotechnology ETF
IBB
+$6.37M

Top Sells

Rank Stock Value
1
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$11.4M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$9.76M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$8.32M
4
OSUR icon
OraSure Technologies
OSUR
+$8.11M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$6.9M

Sector Composition

Rank Sector Weight
1 Healthcare 85.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNST
26
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$6.24M 1.07%
1,556,998
+242,255
+18% +$1.46M
IBB icon
27
iShares Biotechnology ETF
IBB
$9.18B
$5.79M 0.99%
+60,000
New +$6.37M
CDNA icon
28
CareDx
CDNA
$2.48B
$5.03M 0.86%
200,000
– –
DNLI icon
29
Denali Therapeutics
DNLI
$3.67B
$2.07M 0.35%
+100,000
New +$1.81M
QTNT
30
DELISTED
Quotient Limited Ordinary Shares
QTNT
$1.99M 0.34%
+8,125
New +$2.13M
NTGN
31
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
$1.32M 0.23%
263,344
-75,001
-22% -$525K
CRSP icon
32
CRISPR Therapeutics
CRSP
$4.88B
– –
-220,000
Closed -$9.76M
CTMX icon
33
CytomX Therapeutics
CTMX
$690M
– –
-207,500
Closed -$3.84M
GILD icon
34
CALL
Gilead Sciences
GILD
$163B
– –
-50,000
Closed -$3.86M
NEOG icon
35
Neogen
NEOG
$2.59B
– –
-130,000
Closed -$4.65M
OSUR icon
36
OraSure Technologies
OSUR
$286M
– –
-525,000
Closed -$8.11M
JNCE
37
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-375,000
Closed -$2.44M
CLVS
38
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-235,000
Closed -$6.9M
CELG
39
CALL
DELISTED
Celgene Corp
CELG
– –
-50,000
Closed -$4.47M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q4 2018 Portfolio in Review

As of Q4 2018, Casdin Capital held 39 positions worth $585M, down 29% from $823M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Casdin Capital withdrew a net $19.6M in Q4 2018, closing 8 positions and reducing 8 holdings. Its most notable exit was CRISPR Therapeutics, an estimated $9.76M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier.

Against the trend, Casdin Capital opened a new position in iShares Biotechnology ETF worth $5.79M.

  • Casdin Capital's largest Q4 2018 buy was iShares Biotechnology ETF: 60,000 shares worth $5.79M.
  • Casdin Capital added most to Sarepta Therapeutics in Q4 2018, an estimated $13.8M increase.
  • Casdin Capital's biggest Q4 2018 reduction was SANGAMO THERAPEUTICS INC, cutting an estimated $11.4M.
  • Casdin Capital fully exited CRISPR Therapeutics in Q4 2018, selling an estimated $9.76M.
  • Casdin Capital's ten largest holdings make up 58% of its $585M portfolio in Q4 2018.
  • Casdin Capital opened 3 new positions and closed 8 in Q4 2018.
  • Casdin Capital's portfolio value fell 29% quarter-over-quarter to $585M.

Based on Casdin Capital's 13F filing for Q4 2018, filed 13 Feb 2019.